Form 4: Cassava Sciences Director Pierre Gravier Granted 26,500 Stock Options

Cassava Sciences Inc. Director Pierre Gravier was granted 26,500 stock options with an exercise price of $2.11, vesting over one year, as part of the company's amended non-employee director compensation program.

Summary

• Pierre Gravier, a Director at Cassava Sciences Inc. (SAVA), was granted 26,500 stock options.
• The transaction date for this grant was May 23, 2025.
• The exercise price for these stock options is $2.11 per share.
• The options were granted pursuant to the Amended Non-employee Director Compensation Program, which was approved by stockholders on May 23, 2025.
• These stock options will vest over a one-year period at a rate of 1/12 per month.
• The expiration date for these options is May 23, 2035.
• Following this transaction, Pierre Gravier beneficially owns 26,500 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a routine compensation event (stock option grant) to a director, which is a positive for corporate governance as it aligns interests, but does not indicate significant operational or financial news that would dramatically shift sentiment.

Positives

• The grant of stock options aligns the director's financial interests with those of the company's shareholders, promoting long-term value creation.
• The compensation program under which these options were granted was approved by stockholders, indicating transparency and governance adherence.
• Equity-based compensation is a standard practice for attracting and retaining qualified directors.

Future Outlook

The granted stock options will vest monthly over a one-year period, aligning the director's incentives with the company's performance over this timeframe.

Management Comments

• "Form 4 represents grant pursuant to the Amended Non-employee Director Compensation Program approved by stockholders on May 23, 2025."
• "Stock options vest over a one (1) year period at a rate of 1/12 per month."

Industry Context

The grant of stock options to non-employee directors is a common and widely accepted practice across various industries, particularly in publicly traded companies, as a means of compensation and to align the interests of directors with those of shareholders.

Comparison to Industry Standards

• Compensating non-employee directors with equity, such as stock options, is a standard practice in corporate governance across most industries, including biotechnology and pharmaceuticals, to incentivize long-term performance and align interests with shareholders.
• The vesting schedule of one year (1/12 per month) is a typical approach for director equity grants, balancing immediate recognition with retention and performance incentives.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of stock options to a director aligns their interests with long-term shareholder value, as the director benefits from an increase in the company's stock price.

Next Steps

• The granted stock options will continue to vest monthly over the next year, with full vesting expected by May 2026.

Key Dates

Recommendation

Keywords

Cassava Sciences, SAVA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Corporate Governance